Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 04 25; 143(17):1713-1725.

View in: PubMed

subject areas

Adult
Aged
Female
Follow-Up Studies
Humans
Immunotherapy, Adoptive
Lymphoma, Follicular
Male
Middle Aged
Neoplasm Recurrence, Local
Receptors, Antigen, T-Cell
Treatment Outcome

authors with profiles

Peter Riedell